Latest Director Participation News

Adavale Resources has raised $5.15 million in a strongly supported placement to fund an expanded drilling program at its London Victoria Gold Mine and advance regional exploration efforts.

Apollo Minerals has secured a five-year reinstatement of its Couflens exploration permit in France, reviving prospects at the historic Salau tungsten mine alongside promising gold mineralisation. The company also advances exploration in Gabon and Serbia while raising A$6.55 million to fund its growth.

Minbos Resources Limited reported a challenging quarter with significant cash outflows but plans a $1 million share purchase plan to bolster its funding position.

Aland Equity Group Limited has completed significant capital raisings and board restructuring while navigating a challenging quarter for its flagship Growth Fund. The company is positioning itself for expansion into property funds management.

Apollo Minerals has raised $6.5 million through a share placement to advance its Couflens High Grade Tungsten Gold Project in southern France, backed strongly by existing investors and company directors.

True North Copper reports significant drilling success at Mt Oxide’s Aquila Prospect and advances its Cloncurry Copper Project with a new scoping study, backed by a $12.5 million capital raise to fund 2026 growth.

BPH Energy’s December quarter report reveals significant progress in its investee projects amid ongoing legal challenges and strategic capital management. The company balances judicial reviews, regulatory milestones, and funding plans across energy and medical technology sectors.

Pilot Energy has successfully raised $3.44 million through a placement to fund its Cliff Head operations and emerging carbon capture projects, signalling a strategic push into clean energy transition.

Ore Resources Ltd has reported significant high-grade gold intercepts at its Miriam Project, extending mineralisation at Forrest to 850 metres. The company also secured binding options to acquire the Randalls Gold Project and raised A$7.5 million to fund its ambitious 2026 exploration plans.

Nyrada Inc. has secured ethics approval to launch a Phase IIa clinical trial for its heart attack drug Xolatryp®, with patient recruitment set for March 2026. The company maintains a solid cash position of AU$7.12 million as it expands its research into oncology.

Critica Limited has successfully closed the second tranche of its $8 million placement, issuing over 92 million shares and options to accelerate development at its Jupiter Rare Earth Project.

Dreadnought Resources reports a 36% increase in high-grade gold resources at Star of Mangaroon, secures $18 million in funding, and advances critical metals projects with promising drilling results and strategic partnerships.